Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-927 with modified FOLFIRINOX with or without budigalimab versus modified FOLFIRINOX in previously untreated metastatic pancreatic adenocarcinoma
MOH_2021-04-13_009886Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of giloralimab, budigalimab and FOLFIRINOX in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by AbbVie Inc. Started Apr 2021; status: completed.
02
Drugs
giloralimabbudigalimabFOLFIRINOX
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on MOH_2021-04-13_009886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-13_009886.